Biometrics Dept.Chugai Pharmaceutical Co., Ltd., Tokyo, JapanTokyo, Tokyo, Japan
OC 06.3 - Final Analysis Results from a Phase III Study of Emicizumab Prophylaxis for Acquired Hemophilia A (AGEHA)
Saturday, June 24, 202313:30 – 13:45 ET
OC 69.4 - Safety, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Injection of NXT007, an Emicizumab-Based Next-Generation Bispecific Antibody, in Healthy Volunteers (NXTAGE Study)
Wednesday, June 28, 202311:00 – 11:15 ET
